hengrui glp 1 Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 | Tue, 07/15/2025 Hengrui has submitted an IND

At this years USDA Agricultural Outlook Forum panel, some suggested slowing food demand from both GLP-1 drugs and slowing population growth may require agriculture to increase its focus on nutritionally dense food, rather than production volume (Hagstrom, 2025)

For monotherapy, some practitioners recommend periodic breaks to assess baseline function

doi: 10.1016/j.pbb.2011.12.018

Temporary Amenorrhea (No Periods): In exceptional instances, women may completely cease menstruation for some time until their bodies get used to the metabolic changes brought about by Semaglutide

However, weight loss rarely follows a perfectly linear path